Navigation Links
Combination of Thyroid Medicines Not Necessary
Date:2/19/2008

done on the combination and that no clear benefit has been shown to prescribing T3 in addition to T4.

The addition of T3 also makes treatment and monitoring more complex. Treatment with T4 provides steady levels of both T3 and T4 hormones. However, when synthetic T3 is given, it builds up and then dissipates quickly, according to Jonklaas, who added that if patients on combination therapy aren't carefully monitored, they can develop symptoms of thyroid overactivity, such as heart palpitations and trouble sleeping.

In an attempt to put this debate to rest, Jonklaas and her colleagues followed 50 people between the ages of 18 and 65 who needed to have their thyroid removed due to thyroid nodules, cancer or a goiter. None of the volunteers had symptoms of underactive (hypo) or overactive (hyper) thyroid glands at the start of the study.

All of the study participants were treated with T4 alone after surgery.

The researchers measured T4 and T3 levels both before and after surgery and essentially found no change.

"This is further evidence that combination therapy is unlikely to be of use to people who've had thyroid surgery," said Dr. David Cooper, director of the division of endocrinology at Sinai Hospital of Baltimore and director of Johns Hopkins University's thyroid clinic. He wrote an editorial that accompanied the study.

Cooper did point out that there were some people who had slightly lower levels of T3 after surgery and that these people may be the ones who are candidates for combination therapy.

Both Jonklaas and Cooper said the findings are likely applicable to people who have improperly functioning thyroid glands as well, particularly for people with overactive thyroids that either have their thyroids removed or destroyed with radioactive iodine.

More information

To learn more about thyroid medications, read this from the

Copyright©2008 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Combination therapy reverses effects of portal hypertension in rats
3. Combination vaccines okay for infants, study shows
4. Antidepressants and painkillers - a dangerous combination
5. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Drug combination might offer hope for patients deadly brain tumors
8. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
9. Combination targets: some drugs may work best when they work together
10. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combination of Thyroid Medicines Not Necessary
Combination of Thyroid Medicines Not Necessary
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3JAG Media Holdings Inc Amends Articles of Incorporation 58781 1JAG Media Holdings Inc Amends Articles of Incorporation 58781 2Vermillion Announces Return of Eric Fung M D Ph D 14338 1Vermillion Announces Return of Eric Fung M D Ph D 14338 2Vermillion Announces Return of Eric Fung M D Ph D 14338 3Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 1Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 2